Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49446| Title: | Impact of rivaroxaban in cardiovascular disease |
| Authors: | Cardona, Mark Wirth, Francesca Serracino-Inglott, Anthony Xuereb, Robert G. Azzopardi, Lilian M. |
| Keywords: | Rivaroxaban Anticoagulants (Medicine) -- Case studies Warfarin Cardiovascular Disease -- Chemotherapy |
| Issue Date: | 2017-10 |
| Publisher: | European Society of Clinical Pharmacy |
| Citation: | Cardona, M., Wirth, F., Serracino-Inglott, A., Xuereb, R. G., & Azzopardi, L. M. (2017, October). Impact of rivaroxaban in cardiovascular disease. Poster session presented at the 46th European Symposium on Clinical Pharmacy, Heidelberg, Germany. |
| Abstract: | Background and Objective: Compared to warfarin, the novel oral anticoagulant rivaroxaban has uncomplicated dosing with no need for INR monitoring and fewer drug and food interactions, which have been reported to improve adherence to treatment. The objectives were to determine INR control for patients on warfarin and compare warfarin and rivaroxaban with respect to treatment adherence, incidence and severity of bleeding and drug–drug interactions (DDIs). |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/49446 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Impact_of_rivaroxaban_in_cardiovascular_disease_2017_poster.pdf | 442.84 kB | Adobe PDF | View/Open | |
| Impact_of_rivaroxaban_in_cardiovascular_disease_2017.pdf | 90.72 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.